Financial Press Releases
About Avicanna
Strategically positioned to be a front runner in the;
• Development
• Manufacturing and;
• Commercialization of plant-derived cannabinoid-based products
Aug. 18, 2020
Avicanna Closes Non-Brokered Private Placement Raising $2.7 Million
Avicanna Inc. is pleased to announce that it has closed a non-brokered private placement (the “Offering“). Under the Offering, the Company has issued an aggregate of 1,952,410 units (the “Units“) at a price of CAD$1.40 per Unit for aggregate gross proceeds of approximately CAD$2.7 million. Under the Offering, the Company has issued an aggregate of 1,952,410 …
Aug. 17, 2020
Avicanna Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces results for the three and six months ended June 30, 2020.
May 25, 2020
Avicanna Reports First Quarter 2020 Financial Results and Provides Corporate Update
TORONTO, May 25, 2020 /CNW/ – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces results for the first quarter ended March 31, 2020.
April 21, 2020
Avicanna Closes Non-Brokered Private Placement with Group of Strategic Investors and Announces Warrant Re-Pricing
TORONTO, April 21, 2020 /CNW/ – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased …
▪ Avicanna Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update – April 15, 2020
▪ Avicanna Closes First Tranche of Private Placement – January 24, 2020
▪ Avicanna Reports Third Quarter 2019 Financial Results – Nov. 14, 2019
▪ Avicanna Completes its First Exportation of Cannabinoids from Colombia to Canada for Scientific Purposes – Aug 23, 2019
▪ Avicanna Reports Second Quarter 2019 Financial Results – Aug 14, 2019
▪ Avicanna Commences Trading on the TSX Under the Symbol “AVCN” – July 18, 2019
▪ Avicanna Announces TSX Listing Date – July 16, 2019
▪ Avicanna Announces Receipt for Final Prospectus and Conditional Approval for Listing on the TSX – July 10, 2019
▪ Avicanna Closes Oversubscribed $22.1 Million Special Warrant Offering – April 18, 2019
▪ Avicanna Announces Filing of Preliminary Prospectus – January 21, 2019
▪ Avicanna Inc. Acquires 60% Stake in Colombian Medical Marijuana Firm Santa Marta Golden Hemp – August 16, 2018
▪ Avicanna Completes 2nd Equity Financing & Welcomes New Strategic Shareholder – January 29, 2018
▪ Avicanna Closes its First Equity Financing and Announces its Residency at Johnson & Johnson Innovation, JLABS @ Toronto – May 26, 2017
